Summary:
Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Qualified Participants Must:
• Have had at least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, beta version
•
Have had migraine onset before age 50
•
Have a history of migraines typically lasting between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
•
Have a history of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the previous 3 months
Qualified Participants May Receive:
Free medication, Free evaluations, $100.00 per visit.